

12 June 2023

## **Cizzle Biotechnology Holdings Plc**

("Cizzle Biotechnology", "Cizzle", the "Company", or the "Group")

### **Total Voting Rights**

Cizzle Biotechnology, the UK-based diagnostics developer, announces a correction to the total voting rights figure included in the Company's announcement made earlier today.

### **Total Voting Rights**

Following Admission of the New Ordinary Shares, the total number of Ordinary Shares in issue will be 363,841,773 each with equal voting rights. The Company does not hold any rights in treasury. The total voting rights figure can be used by Shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change of their interest in, the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

Capitalised terms used in this announcement shall, unless defined in this announcement or unless the context provides otherwise, bear the same meaning ascribed to such terms in the announcement made by the Company at 7.00 a.m. on 12 June 2023.

### **Enquiries:**

#### **Cizzle Biotechnology Holdings plc**

Allan Syms (Executive Chairman)

#### **Via IFC Advisory**

#### **Allenby Capital Limited**

John Depasquale

Alex Brearley

**+44(0) 20 33285656**

#### **Novum Securities Limited**

Colin Rowbury

Jon Bellis

**+44(0) 20 7399 9400**

#### **IFC Advisory Limited**

Tim Metcalfe

Florence Chandler

**+44(0) 20 3934 6630**

[cizzle@investor-focus.co.uk](mailto:cizzle@investor-focus.co.uk)

### **Notes to Editors:**

#### **About Cizzle Biotechnology**

Cizzle Biotechnology is developing a blood test for the early detection of lung cancer. Cizzle Biotechnology is a spin-out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein

involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.

For more information, please see <https://cizzlebiotechnology.com>

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.